Top

Published in:

01-08-2013 | Note

The virucidal effect against murine norovirus and feline calicivirus as surrogates for human norovirus by ethanol-based sanitizers

Authors: Yuko Shimizu-Onda, Tempei Akasaka, Fumihiro Yagyu, Shihoko Komine-Aizawa, Yukinobu Tohya, Satoshi Hayakawa, Hiroshi Ushijima

Published in: Journal of Infection and Chemotherapy | Issue 4/2013

Abstract

This study examined the virucidal effects of five types of alcohol-based sanitizers including malic acid and sodium malate, or monoethanolamin, in 58 vol % ethanol (pH 4.0, pH 7.1, pH 11.8), 65 vol % ethanol (pH 4.2), and 75 vol % ethanol (pH 4.4) against murine norovirus (MNV) and feline calicivirus (FCV). The virus titer of MNV was reduced in an ethanol dose-dependent manner under the same pH (about 4.0) condition. Virucidal effect against MNV was correlated with pH when the concentration of ethanol was constant (58 vol %). All the ethanol-based sanitizers provided sufficient virucidal effects against FCV. In conclusion, the virucidal effect of the ethanol-based sanitizer at low concentration of ethanol against norovirus (NoV) is increased when the pH is adjusted to a neutral state.

Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 2009;361(18):1776–85.PubMedCrossRef

Center for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep. 2011;60(3):1–15.

Wu HM, Fornek M, Schwab KJ, Chapin AR, Gibson K, Schwab E, et al. A norovirus outbreak at a long-term-care facility: the role of environmental surface contamination. Infect Cont Hosp Epidemiol. 2005;26(10):802–10.CrossRef

Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MPG, Estes MK. Laboratory efforts to cultivate noroviruses. J Gen Virol. 2004;85(pt 1):79–87.

Green KY, Belliot G, Taylor JL, et al (2007) Norovirus. In: Fields virology, 5th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 952–953.

Wobus CE, Thackray LB, Virgin HW 4th. Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol. 2006;80(11):5104–12.PubMedCrossRef

Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW 4th. STAT1-dependent innate immunity to a Norwalk-like virus. Science. 2003;299(5612):1575–8.PubMedCrossRef

Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, Belliot G, et al. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2004;2(12):2076–84.CrossRef

U.S. Environmental Protection Agency: Confirmatory virucidal effectiveness test using feline calicivirus as surrogate for norovirus. http://www.epa.gov/oppad001/pdf_files/confirmatory_virucidal_test.pdf.

10.

Shimizu Y, Ushijima H, Kitajima M, Katayama H, Tohya Y. Murine norovirus as a novel surrogate to evaluate disinfectants for human norovirus. Jpn J Environ Infect. 2009;24(6):388–94.CrossRef

11.

Park GW, Barclay L, Macinga D, Charbonneau D, Pettigrew CA, Vinje J. Comparative efficacy of seven hand sanitizers against murine norovirus, feline calicivirus, and GII.4 norovirus. J Food Prot. 2010;73(12):2232–8.PubMed

12.

Belliot G, Lavaux A, Souihel D, Agnello D, Pothier P. Use of murine norovirus as a surrogate to evaluate resistance of human norovirus to disinfectants. Appl Environ Microbiol. 2008;74(10):3315–8.PubMedCrossRef

13.

Paulmann D, Steinmann J, Becker B, Steinmann E, Steinmann J. Virucidal activity of different alcohols against murine norovirus, a surrogate of human norovirus. J Hosp Infect. 2011;79:378–82.PubMedCrossRef

Title: The virucidal effect against murine norovirus and feline calicivirus as surrogates for human norovirus by ethanol-based sanitizers
Authors: Yuko Shimizu-Onda
Tempei Akasaka
Fumihiro Yagyu
Shihoko Komine-Aizawa
Yukinobu Tohya
Satoshi Hayakawa
Hiroshi Ushijima
Publication date: 01-08-2013
Publisher: Springer Japan
Published in: Journal of Infection and Chemotherapy / Issue 4/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI: https://doi.org/10.1007/s10156-012-0516-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease

Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes

Type IV pilus protein PilA of Pseudomonas aeruginosa modulates calcium signaling through binding the calcium-modulating cyclophilin ligand

Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin

Erratum to: Nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in cardiovascular surgical operations

Use of culture-independent analysis to reveal alteration of intestinal microflora by heat-killed Lactobacillus pentosus in a mouse model of endogenous sepsis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials